المؤلفون: Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K, CLEAR Trial Investigators

المساهمون: Gennigens, Christine

المصدر: New England Journal of Medicine, 384 (14), 1289 - 1300 (2021-04-08)

مصطلحات موضوعية: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Phenylurea Compounds, Programmed Cell Death 1 Receptor, Protein Kinase Inhibitors, Quinolines, Everolimus, pembrolizumab, lenvatinib, Sunitinib, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/adverse effects, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Renal Cell/drug therapy, Carcinoma, Renal Cell/mortality, Everolimus/administration & dosage, Everolimus/adverse effects, Female, Humans, Kidney Neoplasms/drug therapy, Kidney Neoplasms/mortality, Male, Middle Aged, Phenylurea Compounds/administration & dosage, Phenylurea Compounds/adverse effects, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Progression-Free Survival, Protein Kinase Inhibitors/therapeutic use, Quinolines/administration & dosage, Quinolines/adverse effects, Sunitinib/adverse effects, Sunitinib/therapeutic use, Survival Analysis, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Kidney Neoplasms, Medicine (all), General Medicine, Human health sciences, Oncology, Sciences de la santé humaine, Oncologie

العلاقة: http://www.nejm.org/doi/pdf/10.1056/NEJMoa2035716Test; urn:issn:0028-4793; urn:issn:1533-4406

الوصول الحر: https://orbi.uliege.be/handle/2268/300816Test

المؤلفون: Pascal Wolter, Alexandra Karadimou, Jean-Jacques Body, Patrick Schöffski, H. Van Poppel, Ludo Willems, Benoit Beuselinck, Philip R. Debruyne, Annick Rogiers, T. van Cann, R. Elaidi, Robert Paridaens, Herlinde Dumez, Joost Berkers, Evelyne Lerut

المصدر: British Journal of Cancer
British Journal of Cancer, 107 (10

مصطلحات موضوعية: Male, Cancer Research, Pathology, Diphosphonates -- administration & dosage -- adverse effects, Indoles, Phenylurea Compounds -- administration & dosage, Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use, Targeted therapy, bone metastases, Renal cell carcinoma, Antineoplastic Combined Chemotherapy Protocols, Bone Density Conservation Agents -- administration & dosage -- adverse effects, Bone Neoplasms -- drug therapy -- pathology -- secondary, Sunitinib, Neoplasm Metastasis, Indoles -- administration & dosage, Outcome, Bone Density Conservation Agents, Diphosphonates, Protein Kinase Inhibitors -- administration & dosage, Osteonecrosis, Bisphosphonates, Sciences bio-médicales et agricoles, Middle Aged, Protein-Tyrosine Kinases, Sorafenib, Prognosis, targeted therapy, Kidney Neoplasms, Treatment Outcome, Oncology, outcome, Female, Niacinamide -- administration & dosage -- analogs & derivatives, Tyrosine kinase, medicine.drug, Carcinoma, Renal Cell -- drug therapy -- pathology -- secondary, Niacinamide, medicine.medical_specialty, renal cell carcinoma, Bone Neoplasms, Osteonecrosis -- chemically induced, Disease-Free Survival, Kidney Neoplasms -- drug therapy -- pathology, Pyrroles -- administration & dosage, medicine, Carcinoma, Humans, Pyrroles, Carcinoma, Renal Cell, Protein Kinase Inhibitors, bisphosphonates, Retrospective Studies, Osteonecrosis of the jaw, business.industry, Protein-Tyrosine Kinases -- antagonists & inhibitors, Bone metastases, Phenylurea Compounds, medicine.disease, osteonecrosis of the jaw, Concomitant, Cancer research, Clinical Study, business

وصف الملف: 1 full-text file(s): application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdb22c4137af4f142fa2a48d0882b042Test
https://pubmed.ncbi.nlm.nih.gov/23132391Test